167 related articles for article (PubMed ID: 25512476)
1. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety.
Reggia R; Franceschini F; Tincani A; Cavazzana I
J Rheumatol; 2015 Feb; 42(2):193-5. PubMed ID: 25512476
[TBL] [Abstract][Full Text] [Related]
2. Does Abatacept Induce Testicular Toxicity?
Al-Mogairen S
Arch Rheumatol; 2020 Jun; 35(2):220-225. PubMed ID: 32851371
[TBL] [Abstract][Full Text] [Related]
3. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
Navarro Coy NC; Brown S; Bosworth A; Davies CT; Emery P; Everett CC; Fernandez C; Gray JC; Hartley S; Hulme C; Keenan AM; McCabe C; Redmond A; Reynolds C; Scott D; Sharples LD; Pavitt S; Buch MH
BMC Musculoskelet Disord; 2014 Dec; 15():452. PubMed ID: 25539805
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.
Westhovens R; Robles M; Ximenes AC; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Murthy B
Ann Rheum Dis; 2015 Mar; 74(3):564-8. PubMed ID: 25550337
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?
Witte T
Clin Rheumatol; 2015 Apr; 34(4):629-34. PubMed ID: 25604317
[TBL] [Abstract][Full Text] [Related]
6. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
[TBL] [Abstract][Full Text] [Related]
7. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H
Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675
[TBL] [Abstract][Full Text] [Related]
8. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
9. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
[TBL] [Abstract][Full Text] [Related]
10. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
[TBL] [Abstract][Full Text] [Related]
11. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
[TBL] [Abstract][Full Text] [Related]
12. Safety issues and concerns of new immunomodulators in rheumatology.
Selmi C; Ceribelli A; Naguwa SM; Cantarini L; Shoenfeld Y
Expert Opin Drug Saf; 2015 Mar; 14(3):389-99. PubMed ID: 25518908
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
[TBL] [Abstract][Full Text] [Related]
14. Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012.
Sato E; Tanaka E; Ochiai M; Shimizu Y; Kobayashi A; Shidara K; Hoshi D; Sugimoto N; Inoue E; Seto Y; Nakajima A; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 May; 25(3):350-7. PubMed ID: 25619283
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the effectiveness of golimumab 50-mg and 100-mg regimens in patients with rheumatoid arthritis in daily practice.
Sato E; Tanaka E; Nakajima A; Inoue E; Shimizu Y; Yamaguchi R; Ochiai M; Shidara K; Hoshi D; Sugimoto N; Seto Y; Taniguchi A; Momohara S; Yamanaka H
Mod Rheumatol; 2015 Jul; 25(4):528-33. PubMed ID: 25536168
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid Arthritis.
Umemura M; Isozaki T; Ishii S; Seki S; Oguro N; Miura Y; Miwa Y; Nakamura M; Inagaki K; Kasama T
Int J Biomed Sci; 2014 Dec; 10(4):229-35. PubMed ID: 25598752
[TBL] [Abstract][Full Text] [Related]
17. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
19. Priapism after tumor necrosis factor alpha inhibitor use.
Kreitenberg AJ; Ortiz EC; Arkfeld DG
Clin Rheumatol; 2015 Apr; 34(4):801-2. PubMed ID: 25579651
[TBL] [Abstract][Full Text] [Related]
20. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.
Briot K; Rouanet S; Schaeverbeke T; Etchepare F; Gaudin P; Perdriger A; Vray M; Steinberg G; Roux C
Joint Bone Spine; 2015 Mar; 82(2):109-15. PubMed ID: 25557658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
